Potent Rabies Vaccines for Free Ranging Carnivores

针对自由放养的食肉动物的强效狂犬病疫苗

• 批准号: 6805934
• 负责人: Koon Y Pak
• 金额: $ 35万
• 依托单位: MOLECULAR TARGETING TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2005-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6805934
• 关键词: Carnivora; Procyonidae; active immunization; drug design /synthesis /production; epizootiology; immunity; laboratory mouse; oral administration; rabies vaccines; recombinant virus; vaccine development; zoonosis

Rabies is not only a public health problem that causes more than 40,000 human deaths per year worldwide but also causes a tremendous economic burden. In the USA alone, more than one billion dollars are spent annually for control, treatment, and prevention of rabies. In developing countries stray dogs are the major carriers of rabies. However, in North America wildlife species, in particular raccoons and skunks, account for more than 90% of all rabies cases. Oral immunization is the most effective method to control and eradicate rabies in stray dogs and wildlife. Unfortunately, the currently available oral rabies vaccine induces insufficient immunity in dogs and skunks, in the initial phase of this research rabies recombinant viruses have been developed by distinct genetic manipulations designed to eliminate pathogenicity and augment immunogenicity. The specific phase II objectives of this research project are to extend safety and efficacy testing of these newly developed rabies vaccines in laboratory rodents and target animals (raccoon and skunk), and to choose a strain for which a master seed stock will be prepared and characterized and a bioreactor process developed for commercial production. PROPOSED COMMERCIAL APPLICATION: The USDA and APHIS, WS are proposing to expand the oral rabies vaccination program designed to stop the advance of rabies and reduce the incidence of rabies cases in selected states in the US. If this research is able to provide a safer, more potent and cost-effective oral rabies vaccine, the new vaccine could potentially supplant the currently used V-RG vaccine in this program.

狂犬病不仅是一个公共卫生问题，每年造成超过40,000人死亡 在全球范围内，但也会造成巨大的经济负担。 仅在美国，每年花费超过十亿美元用于控制，治疗和预防狂犬病。 在发展中国家，流浪狗是狂犬病的主要携带者。 但是，在北美野生动植物中，尤其是浣熊和臭鼬，占所有狂犬病病例的90％以上。 口服免疫是控制和消除流浪狗和野生动植物中狂犬病的最有效方法。 不幸的是，目前可用的口腔狂犬病疫苗会引起狗和臭鼬的免疫力不足，在这项研究的初始阶段，狂犬病重组病毒是通过旨在消除致病性和增强免疫原性的独特遗传操纵而开发的。该研究项目的特定II期目标是扩展这些新开发的狂犬病疫苗在实验室啮齿动物和靶向动物（浣熊和臭鼬）中的安全性和有效性测试，并选择一种菌株，并为其制定和表征主要的种子种子，并为商业生产开发生物反应器过程。 拟议的商业应用： USDA和APHIS，WS提议扩大口腔狂犬病疫苗接种计划，旨在阻止狂犬病的发展并减少美国选定州的狂犬病病例的发生。 如果这项研究能够提供一种更安全，更有效，更具成本效益的口腔狂犬病疫苗，那么新疫苗可能会取代该计划中当前使用的V-RG疫苗。